+ Meeting requests from service providers or consultants cannot be accommodated +

Chemomab Therapeutics is an asset-centric, Phase 3–ready biotech company developing nebokitug for the treatment of fibro-inflammatory diseases. Following positive Phase 2 results in primary sclerosing cholangitis (PSC) and a successful End-of-Phase 2 meeting with the FDA, nebokitug now has a clearly defined regulatory pathway toward potential approval and is advancing toward initiation of a Phase 3 trial.